Travere Therapeutics (TVTX) Tops Q2 EPS by 14c

Travere Therapeutics (NASDAQ: TVTX) reported Q2 EPS of ($0.65), $0.14 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $54.12 million versus the consensus estimate of $50.4 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Taysha Gene Therapies (TSHA) PT Raised to $11 at Citizens on REVEAL Data Update
• Sionna Therapeutics (SION) Reiterated at Market Outperform by Citizens: Readouts Upcoming